Passage BIO Inc
For the period ended Dec 31, 2023. Filed Mar 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 4, 2024
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| (in thousands, except share and per share data) · · 2023 · · 2022 | ||||||
| Operating expenses: · · · · · | ||||||
| Research and development | | $61,419 | | $86,053 | ||
| Acquired in‑process research and development | | — | | 3,000 | ||
| General and administrative | | 41,580 | | 49,341 | ||
| Impairment of long-lived assets | | | 5,390 | | | — |
| Loss from operations | | (108,389) | | (138,394) | ||
| Other income (expense), net | | 6,327 | | 2,269 | ||
| Net loss | | $(102,062) | | $(136,125) | ||
| Per share information: | | | | | ||
| Net loss per share of common stock, basic and diluted | | $(1.86) | | $(2.50) | ||
| Weighted average common shares outstanding, basic and diluted | | 54,743,490 | | 54,429,023 | ||
| Comprehensive loss: | | | | | | |
| Net loss | | $(102,062) | | $(136,125) | ||
| Unrealized gain (loss) on marketable securities | | | 923 | | | (553) |
| Comprehensive loss | | $(101,139) | | $(136,678) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.